Strengthen the research on precision intervention based on clinical classification and outcomes for metabolic associated fatty liver disease
10.3760/cma.j.cn501113-20250603-00215
- VernacularTitle:加强基于代谢相关脂肪性肝病临床分型与结局的精准干预研究
- Author:
Ruixu YANG
1
;
Jiangao FAN
Author Information
1. 上海交通大学医学院附属新华医院消化内科 脂肪肝中心，上海 200092
- Publication Type:Journal Article
- Keywords:
Fatty liver;
Metabolic associated fatty liver disease;
Prognosis;
Diagnosis;
Therapeutic
- From:
Chinese Journal of Hepatology
2025;33(9):817-821
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a chronic non-communicable disease epidemic which is highly heterogeneous and has reciprocal causation with metabolic disorders, which jointly promote the onset of end-stage of liver diseases, cardiovascular-kidney-metabolic diseases and malignant tumors; hence, it is also referred to as metabolic associated fatty liver disease (MAFLD). The MAFLD characteristics and outcomes cannot be accurately predicted by the classification based on obesity and non-alcoholic steatohepatitis (NASH). Unfortunately, drug development that exclusively focuses on NASH has frequently resulted in failure. Currently, there is an urgent need to strengthen research on clinical classification and precise intervention for MAFLD based on disease outcomes. It is anticipated that the prevention and treatment of cardiovascular-kidney-liver-metabolic diseases will be addressed by emphasizing the diagnosis and intervention of metabolic dysfunction and progressive liver fibrosis, as well as treatment strategies targeting obesity/sarcopenic obesity, thereby alleviating the disease burden and improving patient prognosis.
